INS and type 1 diabetes mellitus: Similar results were seen in a 24-week study of patients with insulin-treated type 1 diabetes (T1DM) [27], in which the miglitol treated group had a small increase in GLP-1, reduced GIP, needed slightly less exogenous insulin and had fewer pre-prandial hypoglycaemic events.